Login to Your Account



'Bureaucracy Gone Bonkers'

Glybera Misses Majority Vote; Gets Third CHMP Rejection

By Nuala Moran
Staff Writer

Wednesday, April 25, 2012
LONDON – The gene therapy Glybera has been rejected for the third time, despite the fact that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) last week voted 16 to 15 in favor of approving the treatment for ultrarare inherited disorder lipoprotein lipase deficiency.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription